Tenderwize
Retour à la recherche

Ranibizumab

AOK Bremen/Bremerhaven·Bremen, Germany·Deadline Nov 04, 2027 · 433 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Verträge 2025-4

52/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

52 / 100

Complexité

58 / 100

Facteurs de risque

The structured data, lot description, and XML notice text contain different contract end dates and start/end periods.

Electronic submission is marked as not allowed, while the notice also refers to email and downloadable participation do...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Open-house supply contracts for pharmaceutical products / active substances under § 130a Abs. 8 SGB V.
  • Ranibizumab lot: contract access for the named active substance, excluding medicines on the BfArM children's medicines list.
Afficher le résumé complet

Open-house supply arrangement for pharmaceutical products in Germany, led by AOK Bremen/Bremerhaven. The notice states that interested pharmaceutical companies may join on equal terms, with no exclusivity and no individual negotiations. One lot is identified for Ranibizumab (ATC S01LA04). The notice contains a major inconsistency: the structured data says the contract runs until 31.12.2027, while the XML notice for the lot states 31.12.2025 and the XML notice text also mentions 31.05.2027 / 01.06.2025. Because of this, deadline and duration should be verified before bidding.

Risques

The structured data, lot description, and XML notice text contain different contract end dates and start/end periods.

Electronic submission is marked as not allowed, while the notice also refers to email and downloadable participation do...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Only pharmaceutical undertakings within the meaning of § 4 Abs. 18 AMG may conclude the rebate contract for the offered medicines.

Certifications

  • For bidders established outside Germany, proof of registration in a comparable register from the home country must be provided in a certified German translation.

Administrative

  • The buyer requests self-declarations on reliability and delivery capability, and a self-declaration on Russia sanctions.

Acheteur

Localisation

Bremen, DEU

Site web

www.aok.de

Identifiant

DE114397726

Activité

Health

Lots (1)

LOT-0001

Ranibizumab

Supply/open-house contract for Ranibizumab (ATC S01LA04) under § 130a Abs. 8 SGB V. The lot excludes medicines on the BfArM list under § 35 Abs. 5a SGB V (children's medicines). Interested pharmaceutical companies or groups of companies may join under identical conditions; no exclusivity and no individual negotiations are stated. The lot is based on notice text and structured data.

SuppliesEU fundedElectronic submission

Localisation

Germany

Catégorie

Pharmaceutical products

Date limite

Expired Dec 31, 2025

Détails de la procédure

Date de publication
04 Nov 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
730881-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30